Capricor Therapeutics (CAPR) Change in Interest Receivables (2013 - 2014)
Capricor Therapeutics (CAPR) posted quarterly Change in Interest Receivables of $593.0 for Q3 2014, up 105.25% year-over-year from $288.91 in Q3 2013, and up 212.52% quarter-over-quarter from -$527.0 in Q2 2014.
Powered by 
Analysis
Capricor Therapeutics (CAPR) Change in Interest Receivables (2013 - 2014) Analysis & Trends
Capricor Therapeutics' Change in Interest Receivables history runs 2 years deep, the most recent figure standing at $593.0 for Q3 2014.
- In Q3 2014, Change in Interest Receivables rose 105.25% year-over-year to $593.0; the TTM figure through Sep 2014 stood at -$2604.0 (changed N/A YoY), while the FY2013 annual figure was -$25028.0, down 199.26% from the prior year.
- Change in Interest Receivables for Q3 2014 stood at $593.0, up from -$527.0 in the prior quarter.
- The five-year high for Change in Interest Receivables was $593.0 in Q3 2014, with the low at -$11292.0 in Q3 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Capricor Therapeutics | 543.30 Mn | 543.30 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2014 | 593.00 |
| Jun 30, 2014 | -527.00 |
| Mar 31, 2014 | 570.00 |
| Dec 31, 2013 | -3,240.00 |
| Sep 30, 2013 | -11,292.00 |
| Jun 30, 2013 | -2,222.00 |
| Mar 31, 2013 | -8,274.00 |